Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Myriad Genetics’s stock price has taken a beating over the past six months, shedding 65.1% of its value and falling to $9.99 ...

Shares of NASDAQ MYGN opened at $10.07 on Wednesday. Myriad Genetics has a 1 year low of $9.36 and a 1 year high of $29.30. The firm has a market cap of $919.48 million, a P/E ratio of -7.75 and a ...

Myriad Genetics has a 1-year low of $9.36 and a 1-year high of $29.30. The firm has a market cap of $885.70 million, a price-to-earnings ratio of -7.46 and a beta of 1.79.

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Kimia Therapeutics, Inc. (Kimia), a biotechnology company generating a chemical atlas for treating human disease, today announced the appointment of Imran S. Haque, Ph.D., to the role of chief ...